Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15912 (Sonefpeglutide) FIH SAD Study
NCT04076293Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) comparing HM15912 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events of HM15912 at 44 days and Number of Participants With Significant Findings Observed for Hematology at 44 days. Started Oct 2019; status: completed.
02
Drugs
sonefpeglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04076293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076293.